CAPVAXIVE Pneumococcal Vaccine Delivers Strong ...

By HEOR Staff Writer

September 17, 2025

What makes the CAPVAXIVE pneumococcal vaccine significant for children and adolescents at higher risk for pneumococcal disease? The CAPVAXIVE pneumococcal vaccine (21-valent conjugate vaccine) demonstrated robust immune responses and broad sero...
Oral Semaglutide Benefits: EMA Approves First Oral GLP-1 RA with Cardiovascul...
Ravulizumab aHUS Reimbursement Reassessment: Navigating New Evidence and Trea...
New Federal Actions to Combat Misleading Prescription Drug Ads in 2025
Ending Unproven Fertility Treatments: NICE Calls for Evidence-Based Care in C...
Medicare ACO Outcomes: Balancing Surgical Benefits and Costs Under the TEAM M...
UK Risks Underestimating Life Sciences Investment Potential
Insights on GLP-1 Therapy in Bariatric Surgery Patients
Impact of Generic Liraglutide Launch on Weight Management and Health Economics
Collaboration Cardiac Surgery: Boosting Surgical Volumes Through Multidiscipl...
Mounjaro Price Increase UK: Impacts on Access and Health Economics
Innovative Strategies of MoonLake Immunotherapeutics HS in Targeting Inflamma...
AMALFI Trial: How Patch-Based ECG Monitoring Could Transform Remote Atrial Fi...